Financials in USD. Standardized financial statements.
A compact view of how Cidara Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.27M | $23.28M | $64.45M | $49.57M | $12.07M | $20.91M | $0 | $0 | $0 | $0 |
| Revenue Growth? | -94.5% | -63.9% | +30.0% | +310.8% | -42.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $36.76M | $0 | $73.09M | $0 | $46.40M | $523,000 | $667,000 | $732,000 | $461,000 |
| Gross Profit? | $1.27M | -$13.48M | $64.45M | -$23.52M | $12.07M | -$25.49M | -$523,000 | -$667,000 | -$732,000 | -$461,000 |
| Gross Margin? | +100.0% | -57.9% | +100.0% | -47.4% | +100.0% | -121.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $177.38M | $13.58M | $97.95M | $18.74M | $83.92M | $62.64M | $63.28M | $55.72M | $48.44M | $32.31M |
| Operating Income? | -$176.10M | -$27.06M | -$33.50M | -$42.26M | -$71.85M | -$41.72M | -$63.28M | -$55.72M | -$48.44M | -$32.31M |
| EBITDA? | -$175.87M | -$26.95M | -$33.36M | -$42.07M | -$70.80M | -$41.40M | -$62.76M | -$55.72M | -$47.70M | -$31.85M |
| Income Before Tax | -$170.29M | -$25.07M | -$33.31M | -$42.47M | -$72.11M | -$41.09M | -$59.02M | -$55.73M | -$48.16M | -$32.19M |
| Income Tax Expense | $0 | $15,000 | $272,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$169.83M | -$22.93M | -$33.58M | -$42.47M | -$72.11M | -$41.09M | -$59.02M | -$55.73M | -$48.16M | -$32.19M |
| EPS? | $-26.75 | $-5.25 | $-9.61 | $-16.20 | $-36.03 | $-26.78 | $-45.62 | $-63.69 | $-66.49 | $-46.76 |
| Diluted EPS? | $-26.75 | $-5.25 | $-9.61 | $-16.19 | $-36.03 | $-26.78 | $-45.62 | $-63.69 | $-66.49 | $-46.76 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality